Exploring the companies and themes that make up this emerging and exciting new sector
The Future of Psychedelic Medicine: Two DIFFERENT Treatment Models
Spiritual journey or clinical therapy? What does the future of psychedelic medicine look like?
Optimi Health Approved to Supply Psilocybin Under Health Canada’s Special Access Program
Optimi Health's subsidiary has been named an approved supplier of psilocybin for Health Canada's SAP access program.
Field Trip Health Ltd. Reports Third Fiscal Quarter 2022 Financial Results and Provides Business Update
During the quarter, Field Trip progressed its strategy of building the leading psychedelic therapy company through its Field Trip Health division and continued to invest in its lead drug development program.
Hawaii Senators Approve Psilocybin Task Force Bill In Committee, With Decriminalization Measures Still Pending
A Hawaii Senate committee on Friday approved a bill to set up a state working group to study the therapeutic benefits of psilocybin mushrooms.
Psychedelic Medicine For PTSD: The Key To U.S. Legal Reforms
There are many valid reasons to push forward with legal reforms to advance psychedelic medicine. In the U.S., however, it is the treatment of PTSD that is bringing Republicans and Democrats together.
Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights
Cybin announces its Q3 results, supported by a conference call. Cash as of Decemeber 31, 2021 of CAD$63.6 million.
Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of Anxiety Disorders
Cybin announces receiving a composition of matter patent for its DMT-derived compound, CYB004 from the the USPTO.
5 Superb Values In Psychedelic Stocks, 5 Different Reasons To Buy
Cheap stocks. Many reasons to invest. We selected five different companies who illustrated these value propositions.
Optimi Health Dealer’s License Granted by Health Canada
Optimi Health announces receiving its Dealer's License from Health Canada, allowing the possession, production and sale of psilocybin.
Elemental Advisors Launches PSYK ETF Focused on the Medical Psychedelics Industry
A new U.S.-based psychedelics ETF will begin trading on the NYSE, symbol "PSYK".
Novamind Hosts Clinical Trial to Advance Ketamine Therapy for End-of-Life Patients
Novamind will host a Phase II clinical trial by the Ketamine Research Foundation for ketamine therapy for the terminally ill.